Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016

  • ID: 3753854
  • Report
  • 141 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aciont Inc.
  • Alimera Sciences, Inc.
  • Astellas Pharma Inc.
  • Biophytis SAS
  • GenSight Biologics S.A.
  • Icon Bioscience, Inc.
  • MORE
Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016

Summary

‘Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016’, provides an overview of the Dry (Atrophic) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration
- The report reviews pipeline therapeutics for Dry (Atrophic) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dry (Atrophic) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Dry (Atrophic) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dry (Atrophic) Macular Degeneration

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aciont Inc.
  • Alimera Sciences, Inc.
  • Astellas Pharma Inc.
  • Biophytis SAS
  • GenSight Biologics S.A.
  • Icon Bioscience, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Dry (Atrophic) Macular Degeneration Overview

Therapeutics Development

Pipeline Products for Dry (Atrophic) Macular Degeneration – Overview

Pipeline Products for Dry (Atrophic) Macular Degeneration – Comparative Analysis

Dry (Atrophic) Macular Degeneration – Therapeutics under Development by Companies

Dry (Atrophic) Macular Degeneration – Therapeutics under Investigation by Universities/Institutes

Dry (Atrophic) Macular Degeneration – Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Dry (Atrophic) Macular Degeneration – Products under Development by Companies

Dry (Atrophic) Macular Degeneration – Products under Investigation by Universities/Institutes

Dry (Atrophic) Macular Degeneration – Companies Involved in Therapeutics Development

Aciont Inc.

Acucela Inc.

Alimera Sciences, Inc.

Allergan Plc

Apellis Pharmaceuticals, Inc.

Astellas Pharma Inc.

Benitec Biopharma Limited

Biophytis SAS

Catalyst Biosciences, Inc.

Cell Cure Neurosciences, Ltd.

Foamix Pharmaceuticals Ltd.

Genentech, Inc.

GenSight Biologics S.A.

GlaxoSmithKline Plc

Icon Bioscience, Inc.

Johnson & Johnson

Kodiak Sciences, Inc.

MacuCLEAR, Inc.

Novartis AG

Ophthotech Corp.

Orphagen Pharmaceuticals, Inc.

pSivida Corp.

Sucampo Pharmaceuticals, Inc.

Sun Pharma Advanced Research Company Ltd.

Dry (Atrophic) Macular Degeneration – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

APL-2 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

avacincaptad pegol sodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BIO-201 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BIO-203 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

brimonidine tartrate implant - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CLG-561 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CNTO-2476 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug for Age Related Macular Degeneration - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug for Wet AMD and Dry AMD - Drug Profile

Product Description

Mechanism of Action

R&D Progress

EG-30 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

emixustat hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

fluocinolone acetonide SR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FMX-103 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gene Therapy for Ocular Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GS-030 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GSK-933776 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ICR-14967 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KSI-401 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

lampalizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MA09-hRPE - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MC-1101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

methotrexate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OCU-100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ONL-1204 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OpRegen - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OpRegen Plus - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RC-1 Alpha - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RST-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for AMD - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Dry Age-Related Macular Degeneration - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tesidolumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TT-231 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

unoprostone isopropyl - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VM-100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Dry (Atrophic) Macular Degeneration – Recent Pipeline Updates

Dry (Atrophic) Macular Degeneration - Dormant Projects

Dry (Atrophic) Macular Degeneration – Discontinued Products

Dry (Atrophic) Macular Degeneration – Product Development Milestones

Featured News & Press Releases

May 05, 2016: RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences

Nov 17, 2015: Biophytis establishes New subsidiary to accelerate clinical development of Maculia

Sep 28, 2015: Alimera Sciences Announces Availability Of Review Paper On Real World Experience With ILUVIEN

Oct 18, 2013: Alimera Sciences Receives Complete Response Letter For ILUVIEN

Oct 01, 2013: Roche to present data on Lampalizumab at investor event

Aug 27, 2013: Roche’s lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration

Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials

May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells

Apr 15, 2013: ACT Treats First Patient With Better Vision In Clinical Trial For Stargardt’s Macular Dystrophy

Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Dry (Atrophic) Macular Degeneration, H1 2016

Number of Products under Development for Dry (Atrophic) Macular Degeneration – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Aciont Inc., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Acucela Inc., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Alimera Sciences, Inc., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Allergan Plc, H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Apellis Pharmaceuticals, Inc., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Astellas Pharma Inc., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Benitec Biopharma Limited, H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Biophytis SAS, H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Catalyst Biosciences, Inc., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Cell Cure Neurosciences, Ltd., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Foamix Pharmaceuticals Ltd., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Genentech, Inc., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by GenSight Biologics S.A., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by GlaxoSmithKline Plc, H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Icon Bioscience, Inc., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Johnson & Johnson, H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Kodiak Sciences, Inc., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by MacuCLEAR, Inc., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Novartis AG, H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Ophthotech Corp., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Orphagen Pharmaceuticals, Inc., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by pSivida Corp., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016

Dry (Atrophic) Macular Degeneration – Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Dry (Atrophic) Macular Degeneration Therapeutics – Recent Pipeline Updates, H1 2016

Dry (Atrophic) Macular Degeneration – Dormant Projects, H1 2016

Dry (Atrophic) Macular Degeneration – Dormant Projects (Contd..1), H1 2016

Dry (Atrophic) Macular Degeneration – Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Dry (Atrophic) Macular Degeneration, H1 2016

Number of Products under Development for Dry (Atrophic) Macular Degeneration – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Aciont Inc.
Acucela Inc.
Alimera Sciences, Inc.
Allergan Plc
Apellis Pharmaceuticals, Inc.
Astellas Pharma Inc.
Benitec Biopharma Limited
Biophytis SAS
Catalyst Biosciences, Inc.
Cell Cure Neurosciences, Ltd.
Foamix Pharmaceuticals Ltd.
Genentech, Inc.
GenSight Biologics S.A.
GlaxoSmithKline Plc
Icon Bioscience, Inc.
Johnson & Johnson
Kodiak Sciences, Inc.
MacuCLEAR, Inc.
Novartis AG
Ophthotech Corp.
Orphagen Pharmaceuticals, Inc.
pSivida Corp.
Sucampo Pharmaceuticals, Inc.
Sun Pharma Advanced Research Company Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll